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Sabin strains of oral poliovirus vaccine (OPV) undergo limited genetic changes during replication in cell cultures, the
gastrointestinal tract of vaccinees, and the central nervous system of monkeys. Some of these changes are associated
with loss of attenuation markers. Here we report the dynamics of mutant accumulation in the Sabin strain of poliovirus type
3 inoculated intraspinally into monkeys. Thr r Ile reversion in amino acid 6 of VP1 (2493 C r U) occurred within the first
few days postinoculation (p.i.), but decreased on later days and completely disappeared by Day 17 p.i. 472 U r C reversion
in the 5*-untranslated region appeared to accumulate slower and by Day 17 completely substituted for the vaccine-type
nucleotide at this site. These results indicate that experimental infection of the central nervous system of monkeys consists
of early and late phases in which a different genetic constitution of the virus is favored. In several isolates one additional
neurovirulent revertant was found: a Phe r Ser at amino acid 91 of VP3 (2034 U r C). Since this mutation was never
detected in vaccine lots and is strongly selected against in cell cultures at temperatures below 38.57, it does not threaten
the safety of OPV. q 1996 Academic Press, Inc.
INTRODUCTION sial (Chumakov et al., 1992, 1993; Tatem et al., 1992;
Weeks-Levy et al., 1991). Therefore, to ensure consis-
Oral poliovirus vaccine (OPV), developed by Sabin,
tency of OPV production, every batch of the vaccine must
consists of live polioviruses of three serotypes, attenu-
be tested for neurovirulence in monkeys (CFR, 1994;
ated by serial passaging in cell cultures and plaque puri-
WHO, 1990).
fication (Sabin, 1955). Each OPV serotype possesses ge-
Recently we developed a sensitive molecular method
netic markers that are believed to be related to attenua-
to quantitate neurovirulent revertants in batches of OPV
tion. These markers include low virulence for monkeys
(mutant analysis by PCR and restriction enzyme cleav-
after inoculation into the central nervous system (CNS)
age, MAPREC) and showed that increased content of
and reduced capacity to replicate at higher temperature
U r C reversions at nucleotide 472 in batches of Type
(rct40) or at reduced concentration of sodium bicarbonate 3 OPV caused the vaccine to fail the monkey neuroviru-
(d-marker) (Sabin, 1957, 1961). However, like other RNA
lence test (MNVT) (Chumakov et al., 1991, 1993). To iden-
viruses, OPV strains are prone to genetic changes upon
tify additional potentially revertible sites, we studied ge-
replication. Poliovirus isolated from vaccinees loses
netic stability of all three types of attenuated poliovirus
some attenuation markers, and passaging vaccine
in cell cultures and by using a new molecular methodstrains in cell culture may also result in gradual deattenu-
identified a few sites that consistently accumulated muta-ation (Benyesh-Melnick and Melnick, 1959; Sabin, 1957,
tions; we are now studying their role in neurovirulenceSabin, 1961). Studies with type 3 poliovirus, performed
(Rezapkin et al., 1994, 1995; Taffs et al., 1995). Anotherduring the past decade both in cell cultures and with
approach to finding genomic sites responsible for deat-isolates from vaccinees, identified at least three unstable
tenuation would be to study the stability of strains in thegenomic sites. A 472 U r C reversion in the 5*-untrans-
CNS of monkeys, since neurovirulent mutations can belated region and a Phe r Ser substitution at amino acid
expected to accumulate upon replication of the virus in91 of VP3 (nucleotide 2034) were shown to increase viral
the CNS of monkeys. Recently we performed such aneurovirulence (Westrop et al., 1989). Another mutation,
study with type 1 OPV and found that, with one exception,a Thr r Ile in amino acid 6 of VP1 (nucleotide 2493), was
all mutations that consistently accumulated in the CNSshown to accumulate rapidly during passages in cell
were previously found in cell cultures (Lu et al., 1996).culture, but its role in neurovirulence remains controver-
The 472-C mutation was found in all batches of type 3
OPV, and its content correlated with results of the MNVT
1 Present address: Johns Hopkins University School of Medicine,
(Chumakov et al., 1991); vaccine lots that passed theBaltimore, MD 21205.
MNVT contained less than 0.9% of 472-C, while batches2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (301) 594-6530. E-mail: CHUMAKOV@HELIX.NIH.GOV. that failed the MNVT had more than 1.1% (Chumakov et
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al., 1993). We wondered how so small an increase in servations argue against a likelihood of significant
changes in mutational profiles during our experiments:the content of a mutation can produce such a marked
difference in the pathological response observed in mon- (i) a cytopathic effect occurred on early days p.i. (2–4),
suggesting that m.o.i. was high, thus limiting the possibil-keys. We postulated that the initial content of revertants
in vaccine lots determines their rate of accumulation and, ity of bottlenecking and occurrence of new reversions;
and (ii) some isolated strains had no mutations that aretherefore, the time at which they reach a critical level.
To examine this hypothesis, we studied the dynamics of known to be rapidly selected in cell culture (e.g., viruses
with no 2493-U on Day 17, or viruses with no 472-C onmutant accumulation during virus replication in the CNS
of monkeys. Days 2 and 4; see results below). This suggests that the
procedure employed in this study was unlikely to result
in a significant distortion of the mutational compositionMATERIALS AND METHODS
of the virus present in original CNS samples.
Juvenile rhesus monkeys were inoculated in the lum-
Fifteen strains were isolated from samples collected
bar region of the spinal cord with 0.1 ml of the Pfizer
on Day 4 from monkeys inoculated with both 0.7 and
substrain (RSO) of the Sabin 3 poliovirus (6.0–6.5 log10 3.7% 472-C viruses, 14 isolates from Day 8, and 7 isolates
TCID50 per monkey) as described elsewhere (CFR, 1994; from Day 17. The content of 472-C and 2493-U mutations
WHO, 1990). Monkeys were sacrificed at time intervals
determined by MAPREC in individual virus isolates varied
after inoculation, and segments of lumbar, thoracic, and
in a broad range and did not correlate with the part of
cervical portions of the spinal cord and the lower part of
the CNS from which they were isolated. However, there
the medulla were frozen at 0707 for subsequent virus
was a clear increase in 472-C with time p.i. and by Day
isolation. We also isolated virus from the lower thoracic
17 it reached 100% in both groups of monkeys. Results
areas of the spinal cords from monkeys sacrificed on
on individual isolates ranged from 0 to 100%, suggesting
Day 17 as a part of routine MNVT of OPV lots. All proce-
that the reversion rate in individual monkeys was very
dures on monkeys were performed under general anes-
different. Extreme variability of mutant content does not
thesia as specified in protocols approved by the Institu-
allow any statistically sound conclusions to be made, but
tional Animal Care and Use Committee, CBER. Homoge-
on average, Day 4 isolates from monkeys inoculated with
nates were prepared in Eagle’s MEM for virus isolation
poliovirus sample having 3.7% 472-C contained more re-
in HEp-2 cells incubated at 347. In most cases cytopathic
vertants than isolates from monkeys inoculated with 0.7%
effects appeared 2–4 days after infection, and cultures
472-C sample (58.5 { 36.1% vs 41.8 { 36.3%). The same
were frozen and thawed three times, clarified by low-
was true for Day 8 isolates (73.5 { 35.0% vs 53.8 {
speed centrifugation, and supernatant fluid was col-
40.0%). This trend suggests that at earlier stages after
lected for further analysis. The contents of revertants at
intraspinal inoculation mutant accumulation may depend
nucleotides 472, 2034, and 2493 were determined by
on initial content of 472-C in the inocula.
MAPREC assay. Procedures for RNA isolation, cDNA
These results demonstrated another interesting phe-
synthesis, PCR, and MAPREC have been described else-
nomenon. Four days after inoculation with a virus sample
where (Chumakov et al., 1991, 1992, 1993; Lu et al., 1993).
containing 0.7% 472-C revertants, an amount that does
not cause increased histological lesions in the CNS of
RESULTS AND DISCUSSION
monkeys, the average content of revertants found in the
CNS isolates was already close to 40%. Samples withTwo groups of four monkeys each were inoculated
with samples of the Sabin type 3 poliovirus spiked with this content of 472-C revertants consistently cause se-
vere lesions and paralysis of monkeys after intraspinaltwo different amounts of 472-C revertant [0.7% 472-C, a
content typical for normal vaccine lots, or 3.7% 472-C, a inoculation (Chumakov et al., 1993). The same may be
true in the case of oral administration of OPV after whichcontent found in OPV lots that failed the MNVT (Chuma-
kov et al., 1991)]. Monkeys were sacrificed on Days 4, 8, the majority of healthy vaccine recipients excreted 472-
C revertants during the first days after vaccination (Evansand 17 postinoculation (p.i.), and samples from various
levels of the CNS were used to isolate virus in cell cul- et al., 1985). Despite the fact that the time course of these
reversions may differ in different hosts and tissues, itture. It is crucial for virus isolation experiments to ensure
that in the process of cultivation in vitro virus does not remains that in both cases neurovirulent reversions oc-
cur quite rapidly while hosts show no signs of the patho-accumulate additional mutations. Since it is well known
that attenuated poliovirus has a maximum genetic stabil- logical process that would otherwise occur if revertant
virus was administered directly. Therefore, it appears thatity at lower temperatures, isolation was performed at 347
and the highest possible multiplicity of infection was during the first few days after poliovirus inoculation a
protective reaction develops in the CNS of monkeys andused to minimize changes of mutational composition of
the isolates. HEp-2 cell cultures were used since poliovi- probably in the intestinal tract of vaccinees. We suggest
that if some critical level of revertants is reached beforerus was shown to possess the highest genetic stability
in these cells (Chumakov et al., 1994). The following ob- this defensive reaction appears, more damage results,
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TABLE 1
Mutant Analysis of Viruses Isolated from the CNS of Monkeys Inoculated Intraspinally with the RSO (Pfizer) Strain of Sabin 3 Poliovirus
Day 2 Day 4 Day 6 Day 8 Day 17
472-C 2493-U 2034-C 472-C 2493-U 2034-C 472-C 2493-U 2034-C 472-C 2493-U 2034-C 472-C 2493-U 2034-C
0 100 0 0 100 0 0 100 3.7 0 100 0 100 0 0
0 100 0 0 100 0 0 100 0 0 100 0 100 0 0
0 100 0 0 100 0 0 100 0 2.9 100 0 100 0 0
0 100 0 0 100 0 0 100 0
0 100 0 0 100 0 0 100 15
0 100 0 0 100 0 0 100 0
2.7 93 0 100 1.3 0
91 20 47 0 100 0
13 78 0 0 100 0
and that this critical level is reached sooner when the U to C reversion at nucleotide 2034, changing Phe to Ser
at amino acid 91 of VP3, one of the major determinantsinoculum has a higher mutant content. The rapid devel-
opment of a protective reaction so early p.i. argues of attenuation (Westrop et al., 1989). This mutation had
never been observed in OPV monopools or in cell cultureagainst the role of antibodies; elucidation of its nature
remains an intriguing prospect. passages (Chumakov et al., 1992). We passaged a CNS
isolate obtained on Day 4 p.i., containing 47% 2034-C, atTo determine whether reversion can occur before 4
days p.i. and to study the dynamics of the appearance two different temperatures, and found that 2034-C in-
creased further in cultures maintained at 38.57, while inof other mutations, we isolated viruses from monkeys 2,
4, 6, and 8 days after inoculation with the RSO (Pfizer) those at 377 it rapidly disappeared. Figure 2 presents
average contents of mutations in three independent pas-strain of the type 3 Sabin poliovirus currently used for
OPV production. In addition, we isolated a number of saging lineages. This result agrees with previous find-
ings suggesting that the mutation at nucleotide 2034 de-strains from samples of the CNS of monkeys inoculated
with commercial vaccine lots made from the RSO strain termines the ts phenotype of type 3 poliovirus (Westrop
et al., 1989). Negative selective pressure against thisand sacrificed on Day 17 as part of routine OPV lot re-
lease tests. The initial content of 472-C in the inocula reversion at the temperature used for vaccine production
(347) explains why it was never found in any vaccinewas 0.4%, 2493-U was 1%, and there was no detectable
2034-C. Table 1 shows the quantities of these mutants monopools that we studied.
The interplay of positive and negative selective pres-in isolates. None of six isolates on Day 2 had reversion
at nucleotide 472, but all had complete reversion at nu- sures directed at different viral mutations under different
cultivation conditions produces a so-called ‘‘passengercleotide 2493. On Days 4 through 8 472-C reversion was
detected in some monkeys. It is notable that the samples
with substantial 472-C reversion had lower contents of
2493-U. None of three isolates at Day 17 had 2493-U
reversion, but all were completely reverted to C at nucleo-
tide 472. These results suggested that there may have
been a succession of mutations during the course of
CNS infection. We analyzed samples obtained in the first
experiment and observed the same trend; the Fig. 1 histo-
gram shows the distribution of 472-C and 2493-U in CNS
isolates from that experiment. It appears that, similar to
the experiment summarized in Table 1, the mutation at
2493 was selected first and then declined while the muta-
tion at 472 increased progressively. Quantitative differ-
ences between the two experiments in the time of ap-
pearance of 472-C may have resulted from differences
FIG. 1. Content of 472-C and 2493-U mutants in individual isolatesin contents of that mutant in the inocula. It also appears
of type 3 poliovirus obtained from the CNS of monkeys sacrificed afterthat both mutations tend to be mutually exclusive, and
experimental inoculation with type 3 poliovirus. Each bar represents
only one isolate had combined content of both mutations results of MAPREC analysis for 472-C (solid bars) and 2493-U (open
significantly exceeding 100%. bars) in isolates from monkeys inoculated with type 3 poliovirus sam-
ples with 0.7 and 3.7% 472-C (data pooled).Another mutation observed in the CNS isolates was a
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and related to neurovirulence. Therefore it is possible
that other mutations may have also occurred and/or dis-
appeared during the progression of the CNS infection.
The succession of 2493-U and 472-C mutations observed
in this study can be explained by assuming that the se-
lective pressures imposed on poliovirus during the early
stages of experimental infection differ from those that
occur later. Presence of a reversion from C to U at nucle-
otide 2493 in a majority of isolates obtained during the
first 8 days after intraspinal inoculation with attenuated
poliovirus clearly shows that the Thr r Ile substitution
in VP1 confers a strong replicative advantage to the virus
early in infection of the CNS, as it does during the virus
replication in cell cultures (Chumakov et al., 1992). A
FIG. 2. Content of 2034-C reversion in a strain isolated from the CNS surprising result of this study is that later in CNS infection
of a monkey sacrificed 4 days after inoculation with type 3 poliovirus.
some unidentified factors select against this mutation,The isolate which originally contained 47% of 2034-C was serially pas-
so that isolates at 17 days p.i. regained the ‘‘attenuated’’saged in cultures of Vero cells at 37 (circles) or 38.57 (triangles).
2493-C configuration. A biphasic selection process, in-
creasing mutation at an early phase, and eliminating it
at a later phase of the CNS infection, implies that theeffect’’—the coselection of incidental mutations that oc-
nucleotide 2493 hardly plays any role in poliovirus neu-cur on the same RNA molecule with some selectable
rovirulence for monkeys, especially considering that allmutation(s). It also may lead to the disappearance of an
isolates obtained on Day 2 after inoculation of a sampleotherwise selectable mutation if a mutation with an even
with low neurovirulence were already completely re-stronger selective advantage occurs on another RNA
verted to 2493-U. This conclusion is in accord with ourmolecule. Reversions at nucleotides 472 and 2034 pro-
previous work which found that poliovirus constructsvide a good example of this situation. Both these rever-
completely reverted at 2493 had no increased neuroviru-sions are selectable over a wide range of temperatures
lence (Chumakov et al., 1992, 1993). In addition, several(see Chumakov et al., 1992, and Fig. 2). We prepared
manufacturers produce OPV from type 3 strains that con-mixtures of strains derived from plasmids with poliovirus
tain 100% ‘‘wild-type’’ 2493-U, yet these vaccines passcDNA containing the above point mutations and pas-
the MNVT and possess a good safety record.saged them in HEp-2 cells. Figure 3A shows that when
472-C and 2034-C were present in the same viral genome
they both accumulated with a rate dependent on the
cultivation temperature. But, as shown in Fig. 3B, these
mutations behaved differently when they were present
in different molecules of RNA and therefore competed
with each other. When passaged in cultures at 34 or 377,
472-C increased while 2034-C decreased, as seen in
previous experiments (see Fig. 2 and Chumakov et al.,
1992); however, at 38.57, 2034-C rapidly accumulated
while 472-C decreased. This result demonstrates that
the selective advantage conferred on poliovirus by 2034-
C at 38.57 was much stronger than that conferred by 472-
C, and as a result the latter disappeared, despite the
fact that, when present alone, 472-C also increases the
replicative capacity of poliovirus at elevated as well as
at lower temperatures.
The results presented in this communication reveal
the complexity of microevolution of attenuated poliovirus
in the CNS of monkeys after experimental inoculation
and suggest the possibility that a similar interplay be-
FIG. 3. Coselection or competition of 472-C and 2034-C revertantstween mutations may occur in natural infections with
during passaging of type 3 poliovirus in HEp-2 cells. (A) The inoculumpoliovirus. It should be pointed out that in this study we
was a mixture of virus strains, one with 472-C / 2034-C (double re-
did not perform extensive sequence analysis of the entire vertant) and the other with 472-U / 2034-U (the conventional Sabin
viral genome, but rather concentrated on three genomic strain). (B) The inoculum was a mixture of virus strains, one with 472-
C / 2034-U and the other with 472-U / 2034-C (two single revertants).sites that have been demonstrated earlier to be unstable
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